ArticleFrontiers in neurology2025
Electroencephalographic biomarkers of antibody-mediated autoimmune encephalitis.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Pediatric MOGAD in the Intensive Care Unit: A Case Series.Neurocritical care · 2026Article
- The electroclinical phenotype of epilepsy following autoimmune encephalitis.Epilepsy & behavior reports · 2026Article
- Electroencephalographic Normalization as a Biomarker of Clinical Recovery in Down Syndrome Regression Disorder.Annals of clinical and translational neurology · 2026Article
- Multi-omics integration in autoimmune encephalitis: from novel biomarker discovery to precision therapeutic strategies.Frontiers in immunology · 2026Review
- Imaging biomarkers in antibody-mediated autoimmune encephalitis.Quantitative imaging in medicine and surgery · 2025Article
- MOGAD-related epilepsy: a systematic characterization of age-dependent clinical, fluid, imaging and neurophysiological features.Journal of neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify electroencephalographic (EEG) biomarkers for different subtypes of antibody-mediated autoimmune encephalitis (AE) and assess their significance in disease severity, treatment response, and prognosis. Methods: The clinical and EEG data from 60 AE patients were analyzed. The relationship between EEG severity in the acute phase and disease severity, treatment response, and prognosis was examined to identify factors contributing to poor outcomes. Results: The cohort included 60 patients with the following subtypes of encephalitis: anti-LGI1 (22), anti-NMDAR (12), anti-GABA Conclusion: EEG is a sensitive and valuable tool for AE and exhibit common and specific features across different AE subtypes. The severity of EEG abnormalities is a strong predictor of disease outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.